Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Abbvie Inc (ABBV)
Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 258,439,328
  • Shares Outstanding, K 1,765,537
  • Annual Sales, $ 58,054 M
  • Annual Income, $ 11,836 M
  • 60-Month Beta 0.48
  • Price/Sales 4.40
  • Price/Cash Flow 7.71
  • Price/Book 20.98
Trade ABBV with:

Options Overview Details

View History
  • Implied Volatility 17.28% ( -0.37%)
  • Historical Volatility 20.14%
  • IV Percentile 8%
  • IV Rank 13.31%
  • IV High 28.31% on 10/19/23
  • IV Low 15.58% on 09/01/23
  • Put/Call Vol Ratio 0.31
  • Today's Volume 32,581
  • Volume Avg (30-Day) 19,216
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 457,734
  • Open Int (30-Day) 448,690

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 2.93
  • Number of Estimates 9
  • High Estimate 3.07
  • Low Estimate 2.89
  • Prior Year 3.60
  • Growth Rate Est. (year over year) -18.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
135.85 +8.92%
on 11/09/23
148.38 -0.28%
on 12/07/23
+5.81 (+4.09%)
since 11/07/23
3-Month
135.85 +8.92%
on 11/09/23
154.88 -4.46%
on 09/20/23
-0.94 (-0.63%)
since 09/07/23
52-Week
130.96 +12.99%
on 06/28/23
168.11 -11.98%
on 01/06/23
-17.43 (-10.54%)
since 12/07/22

Most Recent Stories

More News
Is AbbVie Stock a Buy Now?

AbbVie's business could soon become more diversified.

AGN.AX : 0.500 (+1.01%)
ABBV : 147.97 (+1.09%)
IMGN : 29.37 (+0.10%)
Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?

There's no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has a clear edge.

ABBV : 147.97 (+1.09%)
LLY : 588.27 (-0.17%)
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.

These particular players look cheap right now.

ABT : 104.05 (-0.85%)
ABBV : 147.97 (+1.09%)
MDT : 79.55 (+0.65%)
PFE : 28.63 (-0.56%)
Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis...

ABBV : 147.97 (+1.09%)
BMY : 50.16 (+0.56%)
IMGN : 29.37 (+0.10%)
NVS : 95.93 (-1.15%)
RNA : 8.05 (+1.51%)
TARO : 37.00 (+0.71%)
2 Dividend Stocks to Buy and Hold Forever

These stocks offer much more than reliable dividends.

ABBV : 147.97 (+1.09%)
V : 255.82 (+0.60%)
5 S&P 500 Stocks That Pay a Generous Dividend

Investors are pocketing dividend yields between 4% and 9% with these stocks.

MO : 41.32 (-0.10%)
ABBV : 147.97 (+1.09%)
VZ : 38.65 (+0.39%)
PM : 91.12 (+0.02%)
T : 17.09 (+0.89%)
Why Abbvie Stock Popped Today

The company announces a major deal worth over $10 billion.

ABBV : 147.97 (+1.09%)
IMGN : 29.37 (+0.10%)
Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio

AbbVie is spending more than $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales

$SPX : 4,585.59 (-0.01%)
$DOWI : 36,117.38 (+0.17%)
$IUXX : 16,022.49 (+1.48%)
IMGN : 29.37 (+0.10%)
ABBV : 147.97 (+1.09%)
AbbVie Should Consider a Dividend Cut -- Here's Why

Dividend Kings with above-average yields have been badly underperforming the broader markets.

ABBV : 147.97 (+1.09%)
Medtronic Stock: Bull vs. Bear

The medical device maker's shares have gained a little more than 1% so far this year.

ABBV : 147.97 (+1.09%)
MDT : 79.55 (+0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 152.35
2nd Resistance Point 150.36
1st Resistance Point 149.17
Last Price 147.97
1st Support Level 145.99
2nd Support Level 144.00
3rd Support Level 142.81

See More

52-Week High 168.11
Fibonacci 61.8% 153.92
Fibonacci 50% 149.54
Last Price 147.97
Fibonacci 38.2% 145.15
52-Week Low 130.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar